Wild gorillas carriers of a SIV virus close to the AIDS virusNovember 14, 2006In 2005, 40.3 million people in the world, including 25.8 million in Sub-Saharan Africa, were living with HIV. The question of the origin of HIV-1, responsible for the AIDS pandemic, has been stimulating the scientific community for many years. Some months ago, the team of Martine Peeters, director of research at IRD, and Eric Delaporte, director of the mixed research unit UMR 145 jointly involving the IRD and the University of Montpellier 1, showed the chimpanzee subspecies living in the Congo Basin (2) to be the reservoir of HIV-1 virus group M, the source of the world pandemic and that of another, very rare variant, HIV-1 group N. However, the reservoir of the third HIV-1 group, group O which infects humans (3), remained unidentified up to now. This team announces, in an article in the journal Nature, the discovery of a simian immunodeficiency virus (SIV) infection in wild gorillas. Samples of faeces collected from different communities of gorillas found in the remotest areas of the Cameroon tropical forest were found to contain antibodies against this virus, called SIVgor. The genetic characteristics of the virus were present again in three gorillas living more than 400 km apart. Phylogenetic analysis of SIVgor showed it to be related to HIV-1 group O found in humans, essentially in Cameroon and in neighbouring countries. This discovery of an HIV-1 related virus in wild gorillas does not, however, call into question the fact that chimpanzees are the primary reservoir of SIV/HIV viruses that crop up again in gorillas and in humans. As Martine Peeters of the IRD says, "the viruses of groups M and N are, very clearly, the consequence of inter-species transmission from chimpanzee to humans, whereas the origin of HIV-1 group O is less apparent. It cannot be excluded that chimpanzees infected by HIV-1 group O might have contaminated humans and the gorilla independently, or that the gorilla, having been contaminated by the chimpanzee, might have contaminated humans". This work thus opens up a Pandora's box on the questions and speculations concerning the ability of these viruses to cross over from one species to another. The main challenges facing these teams for future work will be determination of the prevalence, the geographical distribution and biology of SIV infections in these great apes, not forgetting the question of how the gorillas were contaminated. This last point remains a mystery,considered as rare. 1. UMR 145: Fran Van Heuverswijn, Cecile Neel, Florian Liegeois, Christelle Butel, Eric Delaporte and Martine Peeters jointly involving the IRD and the University of Montpellier1 University of Alabama (Beatrice Hahn and her colleagues), University of Nottingham (Paul Sharp and his colleagues) PRESICA Project of Cameroon headed by Eitel Mpoudi-Ngole. 2. Keele BF, Van Heuverswyn F, Li Y, Bailes E, Takehisa J, Santiago ML, Bibollet-Ruche F, Chen Y, Wain LV, Liegeois F, Loul S, Mpoudi Ngole E, Bienvenue Y, Delaporte E, Brookfield JF, Sharp PM, Shaw GM, Peeters M, Hahn BH. Chimpanzee Reservoirs of Pandemic and Nonpandemic HIV-1. Science. 2006 , 313 : 523-6 3. Scientists have known for a long time that the Aids virus shows a very strong genetic variability. Two main types of the virus exist: HIV 1 and HIV 2. HIV 1, the most widely spread in the world, embraces three groups (M, N,O) which manifest different genetic characteristics. Within group M, the most frequent, still 9 further subtypes can be distinguished (A, B, C, D, F, G, H, J, K), genetically close yet distinct. Institut de Recherche Pour le Développement |
|||||||||||||||||||||
| Related Hiv-1 Current Events and Hiv-1 News Articles Hoping for a fluorescent basket case Although recent advances have raised hopes that a protective vaccine can be developed, acquired immunodeficiency syndrome (AIDS) remains a major public health problem. Maternal HIV-1 treatment protects against transmission to newborns Mothers receiving highly active antiretroviral therapy (HAART) to treat HIV-1 infection are less likely than untreated mothers to transmit the virus to their newborns through breastfeeding. Scientists join forces to explain HIV spread in Central and East Africa Scientists studying biology and geography may seem worlds apart, but together they have answered a question that has defied explanation about the spread of the HIV-1 epidemic in Africa. Researchers induce HIV-neutralizing antibodies that recognize HIV-1 envelope protein, lipids For the first time, researchers have experimentally induced antibodies that neutralize HIV-1 and simultaneously recognize both HIV-1 envelope protein and lipids. Link uncovered between viral RNA and human immune response In its fight against an intruding virus, an enzyme in our immune system may sense certain types of viral RNA pairs, according to scientists. In vitro antibody production enables HIV infection detection in window period -- key to safer blood Researchers in Israel and Kenya have shown that the contribution of variable degrees of immune suppression, either due to existing chronic infections such as parasitemias and/or nutrition, in different populations may influence and prolong the serological-diagnostic window period of HIV. AIDS discovered in wild chimpanzees Although the AIDS virus (HIV-1) entered the human population through chimpanzees, scientists have long believed that chimpanzees don't develop AIDS. Penn-Wistar team gains insight into HIV vaccine failure A team of researchers from The Wistar Institute and the University of Pennsylvania reports new evidence refuting a popular hypothesis about the highly publicized failure in 2007 of the Merck STEP HIV vaccine study that cast doubt on the feasibility of HIV-1 vaccines. Genetic Variation Associated With Survival Advantage in African Americans With HIV From the start of the HIV epidemic, it appeared that some of the people who were infected with the virus were able to ward off the fatal effects of the disease longer than others. Study offers insights into failed HIV-1 vaccine trial Following the disbandment of the STEP trial to test the efficacy of the Merck HIV-1 vaccine candidate in 2007, the leading explanation for why the vaccine was ineffective - and may have even increased susceptibility to acquiring the virus - centered on the hypothesis that high levels of baseline Ad5-specific neutralizing antibodies may have increased HIV-1 acquisition among the study subjects who received the vaccine by increasing Ad5-specific CD4+ T-cells that were susceptible to HIV-1 infection. More Hiv-1 Current Events and Hiv-1 News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||